1.06  -0.06 (-5.36%)		06-28 00:00
Open: 1.12 High: 1.13 Volume: 1,912,625		Pre. Close: 1.12 Low: 1.06 Market Cap: 11(M)

Short term
Mid term
Targets	6-month :	20.73	1-year :	24.21
Resists	First :	17.75	Second :	20.73
Pivot price	16.52
Supports	First :	16.36	Second :	15.51
MAs	MA(5) :	16.55	MA(20) :	16.5
	MA(100) :	16.92	MA(250) :	16.12
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	69.6	D(3) :	44
RSI	RSI(14): 59.3
52-week	High :	24.8	Low :	10.26

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LMND ] has closed below upper band by 4.8%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	17.55 - 17.62	17.62 - 17.69
Low:	15.98 - 16.05	16.05 - 16.12
Close:	17.37 - 17.5	17.5 - 17.63

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

Mon, 12 Apr 2021
INVESTIGATION ALERT: Halper Sadeh LLP Investigates TLND, INSW, MLND, ORBC, FI; Shareholders are Encouraged to Contact the Firm - The Daily Freeman

Tue, 13 Oct 2020
3 Net Net Working Capital Stocks to Have a Look At - Yahoo Finance

Tue, 06 Oct 2020
IPO Launch: Spruce Biosciences Closes In On $75 Million IPO - TheStreet

Tue, 23 Jun 2020
Millendo Therapeutics Provides Corporate and Pipeline Update - Business Wire

Thu, 09 Aug 2018
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company - Business Wire

Thu, 09 Aug 2018
Once a multibillion dollar company, OvaScience ends a pennystock vehicle for Millendo's reverse merger - Endpoints News

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	70 (M)
Shares Float	53 (M)
Held by Insiders	27.7 (%)
Held by Institutions	40.2 (%)
Shares Short	16,660 (K)
Shares Short P.Month	16,290 (K)

EPS	-3.41
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	10.1
Profit Margin	-55.2 %
Operating Margin	-35.1 %
Return on Assets (ttm)	-8.4 %
Return on Equity (ttm)	-30.1 %
Qtrly Rev. Growth	29.8 %
Gross Profit (p.s.)	0
Sales Per Share	6.12
EBITDA (p.s.)	-2.9
Qtrly Earnings Growth	0 %
Operating Cash Flow	-119 (M)
Levered Free Cash Flow	191 (M)

PE Ratio	-5.17
PEG Ratio	-0.3
Price to Book value	1.73
Price to Sales	2.86
Price to Cash Flow	-10.35

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.